Microbial @entity1036 and XXXX After the Boston Type 1 Keratoprosthesis.

@entity2194 @entity5517 @entity227 @entity1036 @entity364 @entity86 @entity3225 @entity130
PURPOSE: To determine the incidence, @entity2194 associations, microbiological profile, and clinical course of @entity86 after implantation of the Boston type 1 keratoprosthesis (KPro-1). METHODS: A retrospective chart review was conducted of all cases of the KPro-1 performed at a tertiary eye care center between January 1, 2008, and December 31, 2014. RESULTS: Seventy-five KPro-1 procedures were included in the analysis. @entity86 occurred in 13 eyes (17.3%) with an incidence of 0.064 cases per eye-year. The Kaplan-Meier probability of an infection-free graft was 0.96, 0.90, 0.88, 0.87, and 0.86 at years 1 through 5, respectively. The rate of infections was greater in eyes with @entity2194 (26.3% vs. 8.1%, P = 0.06), especially in those with a history of @entity130 (P = 0.001). There were 8 cases (10.7%) of @entity1036 due to either fungi (5 cases) or bacteria (3 cases). There were 7 cases (9.3%) of @entity3225 due to bacteria (5 cases) or intraocular extension of @entity364 (2 cases). The incidence of @entity1036 and @entity3225 was 0.034 and 0.03 cases per eye-year, respectively. Therapeutic management of the @entity5517 required graft and device removal in 7 eyes (53.8%). After completion of microbiologic treatment, 7 eyes (53.8%) had lost more than 2 lines of the best-corrected preinfection visual acuity, including 5 eyes with @entity3225 that @entity227 or worse. CONCLUSIONS: @entity86 are a serious issue that compromises device retention and visual outcomes after keratoprosthesis implantation.
